comparemela.com

Latest Breaking News On - Institutional investors weigh in on xenon pharmaceuticals - Page 1 : comparemela.com

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

California
United-states
Canada
Steven-gannon
Sherrington-robin
Xenon-pharmaceuticals-price-performance
Cantor-fitzgerald
Ikarian-capital
Xenon-pharmaceuticals-inc
Nasdaq
Xenon-pharmaceuticals
Needham-company

Xenon Pharmaceuticals (NASDAQ:XENE) PT Lowered to $60.00

Xenon Pharmaceuticals (NASDAQ:XENE) PT Lowered to $60.00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada
Steven-gannon
Sherrington-robin
Xenon-pharmaceuticals-inc
Cantor-fitzgerald
Xenon-pharmaceuticals
Insider-activity-at-xenon-pharmaceuticals
Lord-abbett
Canada-life-assurance
Royal-bank
News-ratings-for-xenon-pharmaceuticals-daily
Needham-company

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down Following Analyst Downgrade

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down Following Analyst Downgrade
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Canada
China
Steven-gannon
Sherrington-robin
Needham-company
Financial-services-group-inc
China-universal-asset-management-co
Capital-partners
Nasdaq
Institutional-investors-weigh-in-on-xenon-pharmaceuticals
Royal-bank
Tower-research-capital

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $59.44 Average PT from Analysts

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has earned an average recommendation of “Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued ratings on the stock in […]

United-states
Canada
Wellington
New-zealand-general
New-zealand
America
Sherrington-robin
Steven-gannon
Needham-company
Xenon-pharmaceuticals
Xenon-pharmaceuticals-stock
Timessquare-capital-management

Cantor Fitzgerald Reaffirms Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They currently have a $65.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 52.19% from the company’s current price. […]

Canada
Wellington
New-zealand-general
New-zealand
United-states
America
Stifel-nicolaus
Sherrington-robin
Steven-gannon
Wellington-management-group
Xenon-pharmaceuticals
News-ratings-for-xenon-pharmaceuticals-daily

vimarsana © 2020. All Rights Reserved.